Not Yet Recruiting PHASE2 INTERVENTIONAL 7-arm NCT05524974

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study

Sponsor: Fujian Medical University

Conditions Locally Advanced Gastric Cancer

Interventions Apatinib Mesylate Camrelizumab Nab paclitaxel Oxaliplatin S1

Updated 3 times since 2022 Last updated: Aug 30, 2022 Started: Sep 1, 2022 Primary completion: Sep 1, 2024 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Locally Advanced Gastric Cancer and is currently actively recruiting participants. Fujian Medical University leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Medical University

Data source: Fujian Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fuzhou, China